HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD Says Fast-Track SWIFT Reviews Doubled Over Past Year

Executive Summary

Greater awareness of Fast-Track SWIFT and improved understanding of cases appropriate for the process have nearly doubled the number of SWIFT cases evaluated by the National Advertising Division over the past 12 months, NAD attorney Daniel Range said at the NAD 2022 conference in Washington.

You may also be interested in...



NAD SWIFT Cases Get Swifter, More Frequent As Stakeholders Embrace Fast-Track Process

The BBB National Program Inc. expects to double the number of National Advertising Division SWIFT reviews completed in 2023 compared with last year as stakeholders grow more comfortable with the process. At its annual conference in Philadelphia 19-20 September, NAD said it is speeding up the time it takes to complete both SWIFT and standard track reviews.

Floss By Any Other Name Would Sell In Same Category – BBB National Programs Appeals Panel

NARB panel concluded #1 claims challenged by Oral-B floss products marketer P&G aren’t supported by acceptable evidence that the type of product the claim referenced – flossers  – “is recognized as a consumer-relevant category."

Gatorade Laughs Last About BodyArmor Claims

Coca-Cola's BA Sports argued video comparing its BodyArmor and PepsiCo business Stokely-Van Camp’s Gatorade flavors was a “social media joke” not an ad claim.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152929

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel